Today ChanTest announces the hiring of Chris Mathes, Ph.D., M.B.A. to lead its
business into a new era. Mathes starts September 1st as Chief Commercial
Officer (CCO) and will oversee all sales, marketing and customer relations
activities at ChanTest. He will also contribute to the forward looking and
strategic guidance of ChanTest as a global player in the CRO industry.
(Photo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )
"Chris is a real ion channel guy," said Dr. Arthur "Buzz" Brown, CEO, President
& Founder of ChanTest. "As CCO, he brings a unique mix of science and business
to our company in order to make ChanTest's interface to the world even better."
Dr. Mathes has a Ph.D. in Neuroscience from UCLA and an MBA from Rutgers
University. He has published several ion channel papers in peer reviewed
journals over the past two decades. In the last 10 years, Mathes has been a
pioneer in the development and implementation of automated patch clamp systems
for ion channel safety testing and drug discovery.
"I'm really excited about this opportunity at ChanTest," Mathes said. "ChanTest
is already the market leading ion channel CRO. My goal is to further enhance
the brand and to expand the business. I want to make sure that every
pharmaceutical or biotech lab in the world accesses the ion channel and
scientific expertise available at ChanTest."
About ChanTest Corporation (www.chantest.com)
ChanTest translates the most advanced Ion Channel, GPCR and Transporter
technologies to provide safer, more effective medicines. By combining
electrophysiology, molecular biology and cell culture including cell lines,
stem cells and native cells ChanTest has developed biomarkers, reagents and
services that greatly enhance drug discovery. The Company has alliances in
which its technologies are integrated with medicinal, combinatorial and
computational chemistry, animal models and clinical trials to provide modular
or complete services along the drug development pathway. Since its inception in
1998, ChanTest has tested compounds for more than 500 global pharmaceutical and
biotechnology companies. ChanTest's library of ion channel cell lines,
validated human stem cell-derived cardiomyocytes and predictive nonclinical
cardiac risk assessment program are the most comprehensive available today.
Because of ChanTest's seminal role in cardiac safety and its uncompromising
commitment to quality, ChanTest has been named the "most trusted and most used
fee-for-service provider" for ion channel screening in an independent survey
for the past three years. ChanTest is based in Cleveland, Ohio. For more
information, e-mail firstname.lastname@example.org.
CONTACT: Kate Siver, +1-216-332-1665, email@example.com
SOURCE: ChanTest Corporation